0000929638-24-001532.txt : 20240419 0000929638-24-001532.hdr.sgml : 20240419 20240419075034 ACCESSION NUMBER: 0000929638-24-001532 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240325 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240419 DATE AS OF CHANGE: 20240419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ayala Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001100397 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 841521955 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36138 FILM NUMBER: 24855639 BUSINESS ADDRESS: STREET 1: 9 DEER PARK DRIVE STREET 2: SUITE K-1 CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 BUSINESS PHONE: 732 545 1590 MAIL ADDRESS: STREET 1: 9 DEER PARK DRIVE STREET 2: SUITE K-1 CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 FORMER COMPANY: FORMER CONFORMED NAME: Advaxis, Inc. DATE OF NAME CHANGE: 20050105 FORMER COMPANY: FORMER CONFORMED NAME: GREAT EXPECTATIONS & ASSOCIATES INC DATE OF NAME CHANGE: 19991203 8-K/A 1 a8k.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 25, 2024

Ayala Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware
 
001-36138
 
84-1521955
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)

9 DEER PARK DRIVE, SUITE K-1
MONMOUTH JUNCTION, New Jersey
 
08852
(Address of principal executive offices)
 
(Zip code)

Registrant's telephone number, including area code (732) 545-1590

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


EXPLANATORY NOTE

On February 5, 2024, Ayala Pharmaceuticals, Inc., a Delaware corporation (the “Ayala”), and Immunome, Inc. (“Immunome”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) pursuant to which Immunome agreed to acquire, and Ayala agreed to sell, certain of Ayala’s assets and liabilities related to its AL101 and AL102 programs (the “Asset Sale”), which constitute substantially all of Ayala’s assets. On March 25, 2024, Ayala and Immunome consummated the Asset Sale pursuant to the Asset Purchase Agreement.

On March 29, 2024, Ayala filed with the Securities and Exchange Commission (the “SEC”) a Current Report on Form 8-K (the “Original Form 8-K”) to report the consummation of the Asset Sale. The Asset Purchase Agreement and additional information on the details of the Asset Sale may be found therein. This Amendment No. 1 to the Original Form 8-K amends and supplements Item 9.01 of the Original Form 8-K to provide the pro forma financial information required under Item 9.01(b) of Form 8-K, which Ayala was not able to complete until it filed its Annual Report on Form 10-K for the year ended December 31, 2023, which it did on April 16, 2024.

Item 9.01 – Financial Statements and Exhibits.
 
(b) Pro forma financial information.
 
Ayala’s Pro Forma Financial Information relating to the Asset Sale is as follows:
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

Overview

On October 18, 2023, Advaxis Israel Ltd., a company organized under the laws of the State of Israel and a wholly owned subsidiary of Ayala (“Merger Sub”) merged (the “Merger”) with and into Biosight, Ltd., a privately-held pharmaceutical company organized under the laws of the State of Israel (“Biosight”) developing innovative therapeutics for hematological malignancies and disorders. Following the Merger, Biosight continued as the surviving company and a wholly-owned subsidiary of Ayala.  Ayala and its wholly owned subsidiary Biosight ae referred to collectively herein as the “Company”).

On February 5, 2024, Ayala entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Immunome, Inc. (“Immunome”), pursuant to which Immunome agreed to acquire certain of Ayala’s assets and liabilities related to its AL101 and AL102 programs (the “Asset Sale”). The Asset Sale closed (the “Closing”) on March 25, 2024. Pursuant to the Asset Purchase Agreement, Immunome paid to Ayala an aggregate purchase price of $20,000,000 in cash, 2,175,489 shares (the “Shares”) of Immunome’s common stock, $0.0001 par value (the “Common Stock”), issued at Closing and up to $37,500,000 in cash due upon the achievement of certain development and commercial milestone events set forth in the Asset Purchase Agreement.

Basis of Presentation

The following unaudited pro forma condensed combined financial information reflects adjustments to Ayala’s and BioSight’s historical financial results as reported under U.S. Generally Accepted Accounting Principles (“GAAP”) in connection with the Merger and Asset Sale. The unaudited pro forma condensed combined balance sheet data gives effect to the transactions contemplated by the Asset Purchase Agreement as if they had occurred on December 31, 2023. The unaudited pro forma condensed combined statements of operations data gives effect to the Merger and the transactions contemplated by the Asset Purchase Agreement as if they had occurred on January 1, 2023. All dollar amounts, except per share, are in thousands. It is presented as follows:


 •
The unaudited pro forma condensed balance sheet as of December 31, 2023 has been prepared with the assumption that the transactions contemplated by the Asset Purchase Agreement were completed as of that date.


•
The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2023 was prepared based on (i) the historical audited condensed statement of operations of the Company for the year ended December 31, 2023 and (ii) the historical unaudited consolidated statement of operations of Biosight for the period January 1, 2023 through October 18, 2023, which were both then adjusted for the effect of the transactions contemplated by the Asset Purchase Agreement.

The “as reported” column in the unaudited proforma balance sheet and in the unaudited proforma statement of operations reflect the Company’s historical financial statements for the period presented and do not reflect any adjustments related to the events. Assumptions and estimates underlying the proforma adjustments column are described in the accompanying notes.

The unaudited proforma condensed financial statements have been prepared in accordance with the rules and regulations of SEC Regulation S-X. The unaudited proforma consolidated financial information does not purport to be indicative of the results of operations or the financial condition which would have actually resulted if the Merger and Asset Sale actually occurred on the dates presented or to project the Company’s results of operations or financial position for any future period. This financial information may not be predictive of the future results of operations or financial condition of the Company, as the Company’s future results of operation and financial condition may differ significantly from the proforma amounts reflected herein due to a variety of factors.

The unaudited proforma financial information has been prepared by the Company based upon assumptions deemed appropriate by the Company’s management and are based upon information and assumptions available at the time of

filing this Amendment No. 1 to Current Report on Form 8-K. The following unaudited proforma financial information should be read in conjunction with:


 •
Separate audited financial statements of the Company as of and for the year ended December 31, 2023 and the related notes, included in the Company’s Annual Report on Form 10-K filed with the SEC on April 16, 2024.
The pro forma adjustments to the statement of operations do not include the following:


 •
the non-recurring gain on the Asset Sale or any income tax expense related to the gain on Asset Sale, which will be reflected in the Company’s results for the three months ended March 31, 2024.

•
certain non-recurring transaction expenses of the Asset Sale, estimated to be approximately $1,405,000.

•
amounts paid or to be paid to officers and employees as bonuses and to the directors of the Company following the Asset Sale, in the amount of $4,400,000.

•
the $37,500,000 of contingent cash due to the Company upon the achievement of certain milestones.
Unaudited Pro Forma Condensed Balance Sheet
          
As of December 31, 2023
          
(in thousands)
          
           
 
Condensed Company as Reported
  
Asset Sale Pro Forma Adjustments
  
Pro Forma Combined
CURRENT ASSETS:
          
Cash and cash equivalents
 $                      4,882
  
 $                    13,014
(1)
 $                    17,896
Restricted marketable securities
                               -
  
                       52,212
(2)
                       52,212
Prepaid expenses and other current assets
                         2,646
  
                               -
  
                         2,646
Total current assets
                         7,528
  
                       65,226
  
                       72,754
LONG TERM ASSETS:
          
Intangible asset, net
                         3,898
  
                               -
  
                         3,898
Goodwill
                         4,500
  
                               -
  
                         4,500
Operating lease right of use asset
                            102
  
                               -
  
                            102
Property and equipment, net
                            540
  
                               -
  
                            540
Other assets
                              11
  
                               -
  
                              11
Total long-term assets
                         9,051
  
                               -
  
                         9,051
Total assets
 $                    16,579
  
 $                    65,226
  
 $                    81,805
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY):
          
CURRENT LIABILITIES:
          
Trade payables
 $                      6,076
  
 $                        (725)
(3)
 $                      5,351
Operating lease liabilities
                            166
  
                               -
  
                            166
Accrued expenses and other payables
                         5,554
  
                        (2,283)
(4)
                         3,271
Side letter agreements liabilities
                         8,436
  
                               -
  
                         8,436
Accrued payroll and employee benefits
                            786
  
                               -
  
                            786
Income taxes payable
                               -
  
                       12,974
(5)
                       12,974
Proceeds from Asset Sale
                         4,000
  
                        (4,000)
(6)
                               -
Total current liabilities
                       25,018
  
                         5,966
  
                       30,984
LONG TERM LIABILITIES:
          
Long-term warrant liability
                         6,057
  
                               -
  
                         6,057
Convertible note
                         8,141
  
                               -
  
                         8,141
Uncertain tax position
                         1,771
  
                               -
  
                         1,771
Long-term operating lease liabilities
                                9
  
                               -
  
                                9
Total non-current liabilities
                       15,978
  
                               -
  
                       15,978
STOCKHOLDERS' EQUITY (DEFICIENCY):
          
Common stock
                              12
  
                               -
  
                              12
Additional paid-in capital
                     172,797
  
                               -
  
                     172,797
Accumulated deficit
                    (197,226)
  
                       72,195
(7)
                    (137,966)
     
                              39
(8)
  
     
                      (12,974)
(5)
  
Total shareholders' equity (deficiency)
                      (24,417)
  
                       59,260
  
                       34,843
Total liabilities and shareholders' equity (deficiency)
 $                    16,579
  
 $                    65,226
  
 $                    81,805

Unaudited Pro Forma Condensed Combined Statement of Operations
                    
Year ended December 31, 2023
                          
(in thousands except per share and share data)
                          

                           
   
Company As Reported
For the Year Ended December 31, 2023
Biosight
For the Period January 1, 2023 through October 18, 2023
Merger Pro Forma Adjustments
Pro Forma Company Post Merger
Discontinued Operations
Company Post Asset Sale
Revenue
  
 $                       13
  
 $                        -
  
 $                   -
  
 $              13
  
 $               (13)
(10)
 $               -
  
Cost of revenue
  
                        (13)
  
                           -
  
                      -
  
                (13)
  
                    13
(10)
                 -
  
Gross profit
  
                          -
  
                           -
  
                      -
  
                 -
  
                    -
  
                 -
  
Operating expenses:
                          
Research and development
  
                   24,081
  
                      7,114
  
                      -
  
           31,195
  
            (20,544)
(11)
           10,651
  
General and administrative
  
                   12,185
  
                      1,686
  
                      -
  
           13,871
  
                    -
  
           13,871
  
Total operating expenses
  
                   36,266
  
                      8,800
  
                      -
  
           45,066
  
            (20,544)
  
           24,522
  
                           
Operating loss
  
                  (36,266)
  
                     (8,800)
  
                      -
  
         (45,066)
  
             20,544
  
         (24,522)
  
Financial income (expense), net
  
                  (15,718)
  
                      2,151
  
               (2,236)
(9)
         (15,803)
  
                    -
  
         (15,803)
  
Loss before income tax
  
                  (51,984)
  
                     (6,649)
  
               (2,236)
  
         (60,869)
  
             20,544
  
         (40,325)
  
Income tax benefit
  
                     3,912
  
                           -
  
                      -
  
            3,912
  
                    -
  
            3,912
  
Net loss
  
 $               (48,072)
  
 $                  (6,649)
  
 $             (2,236)
  
 $      (56,957)
  
 $          20,544
  
 $      (36,413)
  
                           
Net loss per share basic & diluted
  
 $                   (7.99)
                  
 $          (3.39)
  
Weighted average number of common shares outstanding basic & diluted
               6,019,063
                  
    10,733,646
(12)

Notes to the Unaudited Pro Forma Financial Statements:
(dollars in thousands, except share and per share amounts)

The pro forma adjustments are based on preliminary estimates and assumptions by management that are subject to change. The following adjustments have been reflected in the unaudited pro forma financial information.

(1)
Pro forma adjustment represents the cash received at Closing from the Asset Sale.

     
Gross proceeds from sale, excluding contingent consideration
  
 $            72,212
Fair value of 2,175,489 shares of Immunome common stock
  
              (52,212)
Net cash proceeds from sale
  
               20,000
Reimbursement of expenses
  
                     39
Direct payment of certain vendor invoices
  
                (3,025)
Non-refundable deposit from Immunome
  
                (4,000)
Cash received at Closing
  
 $            13,014

(2)
Pro forma adjustments for 2,175,489 shares received from Immunome based on market close price of such shares on the Nasdaq Capital Market of $24.00 per share. Of the 2,175,489 shares received, the Company has agreed with Immunome that it may not sell more than 50% of the shares in the first six months following the Closing of the Asset Sale, but there are no such restriction on the remaining 50% of the shares.  The resale by the Company of the Shares has been registered by Immunome under the Securities Act through the filing of a Registration Statement on Form S-3 (SEC File No. 333-278490), which was effective under the Securities Act upon filing with the SEC on April 3, 2024, and thus the Company can sell the Shares (subject to the contractual restriction described in this paragraph) at any time.

(3)
As part of the cash consideration at Closing, Immunome paid $3,025 of the Company’s liabilities directly to vendors of the Company, at the Company’s discretion. Of this amount, $725 is in trade payables and $2,300 is in accrued expenses and other payables.

(4)
Pro forma adjustment for estimated net change in accrued expenses and other payables:

Estimated net change in Accrued expenses and other payables
    
   
 Amounts
Estimated transaction expenses accrued at Closing
  
 $              1,405
Direct payment of certain vendor invoices (3)
  
                (2,300)
Book value of liabilities assumed by Immunome
  
                (1,388)
Net change in accrued expenses and other payables
  
 $             (2,283)

(5)
Pro forma adjustment to accrue estimated income taxes owed as a result of the Asset Sale:

Net gain on Asset Sale
  
 $            72,195
Estimated deductions
  
              (29,072)
   
               43,123
Estimated income tax rate:
    
Federal
  
21.00%
State
  
9.09%
   
30.09%
Estimated income taxes payable
  
 $            12,974

(6)
Pro forma adjustment to remove $4,000 that had been paid upon entering into an exclusivity agreement with Immunome in December 2023, and has been recorded as a liability until Closing.

(7)
Pro forma adjustment to reflect the estimated net gain from the Asset Purchase Sale:

Gross proceeds from sale, excluding contingent consideration
  
 $            72,212
Estimated transaction expenses accrued at Closing
  
                (1,405)
Book value of liabilities assumed by Immunome
  
                 1,388
Net gain on Asset Sale
  
 $            72,195

(8)
Pro forma adjustment to account for $39 received in cash for Company expense reimbursements.

(9)
Pro forma adjustment to remove change in fair value of Biosight’s warrants to purchase Biosight’s common stock. These warrants were cancelled as a result of the Merger.


(10)
Pro forma adjustment to remove licensing agreement revenue and related cost generated from technology sold to Immunome.


(11)
Pro forma adjustment to remove research and development expenses related to assets sold to Immunome.


(12)
Pro forma adjustment to weighted average common shares outstanding related to the Merger:


   
Year Ended December 31, 2023
Weighted average Company shares outstanding - basic and diluted
  
           6,019,063
     
Adjusted for:
    
Shares issued to Biosight shareholders, as if the Merger occurred on
January 1, 2023
           4,714,583
Pro forma adjusted weighted average shares outstanding – basic and diluted
  
         10,733,646
     
Pro forma net loss per share – basic and diluted
  
 $           (36,413)
     
Pro forma net loss per common share – basic and dilutive
  
 $              (3.39)




 
(d) Exhibits
 
Exhibit
Number
Description
 
+ Certain schedules and exhibits to this agreement have been omitted in accordance with Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission on request.

† Certain confidential information contained in this document, marked by ***, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential.

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

Date:  April 19, 2024
AYALA PHARMACEUTICALS, INC.
 
 
 
 
 
 
By:
/s/ Kenneth A. Berlin
 
 
President and Chief Executive Officer
 

 

 EX-101.SCH 2 adxs-20240325.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 adxs-20240325_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number No Trading Symbol Flag EX-101.PRE 4 adxs-20240325_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
Mar. 25, 2024
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag false
Document Period End Date Mar. 25, 2024
Entity File Number 001-36138
Entity Registrant Name Ayala Pharmaceuticals, Inc.
Entity Central Index Key 0001100397
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 84-1521955
Entity Address, Address Line One 9 DEER PARK DRIVE
Entity Address, Address Line Two SUITE K-1
Entity Address, City or Town MONMOUTH JUNCTION
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08852
City Area Code 732
Local Phone Number 545-1590
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 20 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://ayala.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports a8k.htm adxs-20240325.xsd adxs-20240325_lab.xml adxs-20240325_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "a8k.htm": { "nsprefix": "adxs", "nsuri": "http://ayala.com/20240325", "dts": { "inline": { "local": [ "a8k.htm" ] }, "schema": { "local": [ "adxs-20240325.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "adxs-20240325_lab.xml" ] }, "presentationLink": { "local": [ "adxs-20240325_pre.xml" ] } }, "keyStandard": 20, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 20 }, "report": { "R1": { "role": "http://ayala.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240325to20240325", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "a8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240325to20240325", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "a8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r0" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r0" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r0" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r0" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://ayala.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r4" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000929638-24-001532-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000929638-24-001532-xbrl.zip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Ɇ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end XML 16 a8k_htm.xml IDEA: XBRL DOCUMENT 0001100397 2024-03-25 2024-03-25 false 0001100397 8-K/A 2024-03-25 Ayala Pharmaceuticals, Inc. DE 001-36138 84-1521955 9 DEER PARK DRIVE SUITE K-1 MONMOUTH JUNCTION NJ 08852 732 545-1590 false false false false false